Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan

Abstract

Background

Hepatitis B virus carriers who receive systemic cancer chemotherapy have been found to be at a higher risk of hepatitis B virus reactivation. However, lack of standard prophylaxis protocol resulted in life-threatening adverse events.

Objective

This retrospective study is to investigate prevalence and chemotherapy drug-induced hepatitis B virus reactivation in all types of cancer patients and establish an institutional clinical practice protocol.

Methodology: This retrospective cohort study evaluated the incidence of hepatitis B virus infection, the pre-chemotherapy screening rate of hepatitis B surface antigen (HBsAg), and the severity of hepatitis B virus reactivation of cancer patients receiving intravenous chemotherapy between 2013 and 2014. Patients receiving local chemotherapy with intra-cavity instillation, drug- or alcohol-related hepatitis, or chemotherapy for immune diseases were excluded.

Results

In total 784 patients, 404 patients (51.53%) underwent hepatitis B virus serum antigen (HBsAg) testing before chemotherapy, and 61 patients (7.78%) tested positive. Only 32 patients (4.08%) received prophylactic hepatitis B virus antiviral therapy. Patients receiving prophylactic antiviral drugs were significantly lower risk of hepatitis B virus reactivation than nonprophylaxis (relative risk, RR: 0.53, number needed to treat, NNT: 12). Moreover, our study found specific single or combined chemotherapy that may cause hepatitis B virus reactivation different from those of other studies conducted in Western countries. The differences may refer to enzymes, proteins and immune response of patients.

Conclusions

Our findings indicate that cancer patients receiving prophylactic antiviral drugs remain at risk of hepatitis B virus reactivation during chemotherapy. Therefore, the hepatitis B virus screen and chemotherapy control system was established in 2017 to reduce the risk of hepatitis B virus reactivation and improve patient safety.

Keywords

Hepatitis B virus cancer chemotherapy prophylaxis hepatitis B virus reactivation

Get full access to this article

View all access options for this article.

References

Lavanchy

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

J Viral Hepat 2004; 11: 97–107.

Sarin

Kumar

Lau

, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1–98.

Liu

Chen

, et al. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013; 7: 316–326.

Loomba

Rowley

Wesley

, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519–528.

Paul

Saxena

Terrin

, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 2016; 164: 30–40.

Sanagawa

Hotta

Kataoka

, et al. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med 2018; 7: 2269–2279.

Chen

Tien

Cheng

, et al. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterol 2018; 18: 6.

Hsu

Tsou

Lin

, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59: 2092–2100.

Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology 2018; 67: 1560–1599.

10.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370–398.

11.

Reddy

Beavers

Hammond

, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215–219; quiz e216–217.

12.

Lok

McMahon

BJ.

Chronic hepatitis B.

Hepatology 2007; 45: 507–539.

13.

Liaw

Brunetto

Hadziyannis

The natural history of chronic HBV infection and geographical differences.

Antivir Ther 2010; 15: 25–33.

14.

Huang

Hsiao

Hong

, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765–2772.

15.

Yeo

Hossain

Lim

, et al. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: an observational study. J Oncol Pharm Pract 2019; 25: 1042–1052.

16.

Liu

Xiao

Xue

, et al. Prophylactic use of entecavir for lymphoma patients with past hepatitis B virus infection: a randomized controlled trial. Clin Lymphoma Myeloma Leuk 2019; 19: 103–108.

17.

Lin

, et al. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol 2018; 30: 925–929.

18.

Perrillo

Gish

Falck-Ytter

YT.

American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Gastroenterology 2015; 148: 221–244.

19.

Lok

Liang

Chiu

, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–188.

20.

Cheng

Hsiung

, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320–1328.

21.

Yeo

Chan

Zhong

, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307.

22.

Yeo

Chan

, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927–934.

23.

Yeo

Chan

Leung

, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605–611.

24.

Lin

Kao

JH.

Perspectives and control of hepatitis B virus infection in Taiwan.

J Formos Med Assoc 2015; 114: 901–909.

25.

Cheung

Seto

Lai

, et al. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int 2016; 10: 407–414.

26.

Bui

Wong-Sefidan

Reactivation of hepatitis B virus after withdrawal of erlotinib.

Curr Oncol 2015; 22: 430–432.

27.

Lok

McMahon

BJ.

Chronic hepatitis B: update 2009.

Hepatology 2009; 50: 661–662.

28.

Voican

Mir

Loulergue

, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27: 2172–2184.

29.

Kawsar

Shahnewaz

Gopalakrishna

, et al. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis. Clin Adv Hematol Oncol 2012; 10: 370–378.

30.

Hsu

Hsiung

, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008; 47: 844–853.

31.

Long

Jia

, et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 2011; 127: 705–712.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB